Anesthesia Research
September 13, 2026
Camilla Teixeira Pinheiro Gusmão, Batuhan Özen, Marina Seixas Studart E Neves et al.
Background/Objectives: Fibromyalgia (FM) is a nociplastic pain syndrome characterized by chronic widespread pain, fatigue, sleep disturbance, cognitive dysfunction, and heightened sensitivity to somatic and environmental stimuli. Depressive symptoms and major depressive disorder (MDD) frequently co-occur with FM and are associated with greater disability, pain catastrophizing, sleep disruption,...
BMJ Open
July 13, 2026
Thomas D Meyer, Lauren N Vale, Maya Ibrahim et al.
Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal...
European Psychiatry
April 1, 2025
Ilídio Oliveira, A. L. Stephany, M. L. Geremias et al.
Introduction Anxious depression (AxD) as an independent diagnostic has been controversial, with many suggesting it as a transient state and others highlighting evidence of a worse outcome, severity, and increased suicide risk. The International Classification of Diseases (ICD-11) lists a related concept under 6A73, Mixed depressive and anxiety disorder. Previous literature on ketamine’s...
Brain Stimulation
2024
Charles R Conway, Scott T Aaronson, Harold A Sackeim et al.
16 citations
RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs),...
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
September 2009
Lara C Assis, Gislaine T Rezin, Clarissa M Comim et al.
Clinical findings suggest that ketamine may be used for the treatment of major depression. The present study aimed to compare behavioral effects and brain Creatine kinase activity in specific brain regions after administration of ketamine and imipramine in rats. Rats were acutely given ketamine or imipramine and antidepressant-like activity was assessed by the forced swimming test; Creatine...
Progress in neuro-psychopharmacology & biological psychiatry
April 30, 2009
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety disorders and major depression. Additionally, studies have shown that ketamine induces antidepressant effects in humans as well as in rodents subjected to animal models of depression. In this context, the present...
Progress in neuro-psychopharmacology & biological psychiatry
January 1, 2008
Lêda S B Garcia, Clarissa M Comim, Samira S Valvassori et al.
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor. Clinical findings point to a rapid onset of action for ketamine on the treatment of major depression. Considering that classic antidepressants may take long-lasting time to exhibit their main therapeutic effects, the present study aims to compare the behavioral effects and the BDNF...